We would love to hear your thoughts about our site and services, please take our survey here.
Cameroon: natural gas market still “non-competitive” according to public authorities
posted the May 17, 2019by Energies Media
This lack of competition in the use of natural gas for electricity generation leads to “still very high” costs of production factors for manufacturing firms, according to the government
The costs of the factors of production of manufacturing companies in Cameroon, as regards the generation of electricity from natural gas, remain “still very high” , according to the report made at the cabinet meeting chaired on April 25 in Yaounde by Prime Minister Joseph Dion Ngute .
The government, which has not, however, officially presented figures on the cost of access to electricity from natural gas, calls into question the "non-competitive nature of the Cameroon natural gas market, linked to the reduced number of operators in this sector. "
The supply of electricity from natural gas has been provided in Cameroon since 2012-2013 by two main operators: Kribi Power Development Company ( KPDC ) - a subsidiary of the British investor Globeleq - which has a 216 MW gas plant in Kribi (South Cameroon), and Gaz du Cameroun - a subsidiary of Britain’s Victoria Oil and Gas - which also supplies natural gas to a 30 MW gas plant in Douala, in the Littoral region. These plants supply their energy directly to the national distribution network operated by Eneo .
Gaz du Cameroun also supplies gas to individuals, mainly companies located in the industrial areas of Bassa and Bonabéri in the Littoral region.
According to the National Hydrocarbons Corporation (SNH), Cameroon produces about 180 million cubic feet of natural gas per day , but only 34 million cubic feet of gas per day is absorbed by the national market whose size is judged " embryonic " .
To improve the level of national consumption of natural gas in meeting electricity needs, SNH is already planning to set up a 300 MW gas-fired plant in Limbe (South-West) and conversion to gas. several diesel or fuel-fired power plants, pending the arrival of other operators.
https://energies-media.com/cameroun-marche-gaz-naturel-encore-non-concurrentiel/
Wow, you really quoting from that site! Lol
Same people different user names! You have to laugh...………..
"Tom Winnifrith must have blotted his copy book at one time with London South East, because whenever anyone mentions hos website it gets blocked by LSE and is replaced with a series of asterisks - automatically!!!"
Well done LSE! He blotted his copy book when he crawled out into this world! :-)
Are you really that stupid-lol
LSE are not up at 01:15 in morning going through posts!
Looks like you tried to post a webpage link that either doesn't exist anymore or you can't even manage to C&P correctly!
How many times have you been banned by LSE, only to reappear with a new username? :-)
A reply after 4 minutes! lol
more lies from you! :-)
"The potential of our pipeline is illustrated by the expected newsflow from our other clinical portfolio programmes and we look forward to updating the market as these progress."
https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=14292131
Successful FDA and Paul Ehrlich Institut meetings on design of Phase III PQ Grass trial, now planned to commence in H2 2020
25 April 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the outcome of successful discussions with the Paul Ehrlich Institut (PEI) in Germany and the Food and Drug Administration (FDA) in the US regarding the pivotal Phase III PQ Grass trial design. The trial, being planned for the US and Europe, will evaluate the efficacy and safety of the Group's short course, aluminium-free pre-seasonal immunotherapy in the prevention of the symptoms of allergic rhinoconjunctivitis caused by grass pollen.
The Group presented positive results from its Phase II PQ Grass trial to the PEI and FDA and agreement was reached on the dose to progress into Phase III, as well as other essential features of the trial design. Accordingly, in order to finalise the design of the trial and incorporate the latest clinical evidence, the trial is expected to commence in H2 2020, to be aligned with the 2020/2021 allergy season.
The Group continues to make good progress with its broad clinical pipeline. A readout of the Phase I Acarovac MPL trial for house dust mite allergies is expected in Q2 2019. Manufacturing scale-up of the Group's Polyvac Peanut product, which is critical to ensure commercial manufacture in a consistent manner for clinical trials and in GMP conditions, is progressing well. The Phase I first-in-human trial for Polyvac Peanut is now expected in H1 2020 as we complete the pre-clinical work in advance of human dosing next year.
The commercial business continues to trade in line with market expectations and gain market share, and the Group remains well-funded to progress its commercial and clinical programme into 2021. As announced in the 6 March 2019 Interim Results, the Group had a cash balance of £31.6m at 31 December 2018.
Manuel Llobet, CEO at Allergy Therapeutics, stated: "With the positive outcomes from our meetings with the FDA and Paul Ehrlich Institut, we have agreed design of our Phase III PQ Grass trial, including patient number requirements and statistical measures.
"Given the sensitivity of clinical trials in allergic rhinitis to the subjective nature of patient-reported outcomes, it is important that we incorporate any potential learnings from our recent trials into the final trial design for PQ Grass. Given the PQ Grass trial is expected to commence in H2 2020 we are confident that we have time to amend the protocol accordingly if required. This product has the potential to become a much-needed treatment option for the estimated 25-30% of the EU and US populations who are allergic to grass pollen1, and we believe that the PQ Grass trial will enable us to demonstrate the efficacy of this short-course grass pollen immunotherapy.
"The potential of our pipeline is illustrated by the expected newsflow
Highlighting that SNH updated their website regarding ‘Gas Supply to Industries’:
Gas supply to Douala-based industries for energy production
The Logbaba Association, comprised of SNH and its partner Gaz du Cameroon, is producing the natural gas reserves of the eponymous field, located in the outskirts of Douala, the economic capital of Cameroon, to supply industries in the Bassa and Bonaberi areas with clean energy, cheaper than fuel oil or diesel.
As of March 2019, 41 of the most important industrial companies have converted their burners and now use natural gas as a source of energy. The gas distribution network is currently being extended to permit the connection of other industries. It now extends over some 50 km.
http://www.snh.cm/index.php/en/gas-up/gas-supply-to-douala-based-industries-for-production-of-energy
(Lets see how long it takes the usual suspects to put a negative spin on the above :-) )
lol, just buy back, daft bugger! :-)
pshepp, thank you
lol
LSE is a breading ground for short term traders!
get a life! :-)
finished early today! All bought back in? Rhet.
You actually got something right, well done!
No doubt another lot of stupid posts from the short term traders tomorrow, whatever! :-)
It's a share BB, you expect shite to be posted! :-)
Very exciting times for VOG over the next few months, just ignore the short term traders who like to waffle on and on and on!
Very exciting times for VOG over the next few months, just ignore the short term traders who like to waffle on and on and on!